Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Phase 2 Completed
34 enrolled 22 charts
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Phase 2 Completed
53 enrolled 17 charts
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase 1/2 Completed
46 enrolled
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
Phase 2 Completed
261 enrolled 10 charts
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
Phase 1/2 Completed
127 enrolled 18 charts
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
Phase 1 Completed
18 enrolled
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase 2 Completed
53 enrolled 11 charts
AZD2171 to Treat Prostate Cancer
Phase 2 Completed
59 enrolled 12 charts
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
Phase 2 Completed
74 enrolled 11 charts
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Phase 2 Completed
24 enrolled 12 charts
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
Phase 2 Completed
22 enrolled 23 charts
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
Phase 2 Completed
60 enrolled 8 charts
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Phase 2 Completed
54 enrolled 12 charts
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Completed
39 enrolled 9 charts
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase 1 Completed
55 enrolled
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
44 enrolled 8 charts
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
Phase 2 Completed
26 enrolled 9 charts
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
47 enrolled 15 charts
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
Phase 2 Completed
6 enrolled
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
Phase 1 Completed
47 enrolled
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
20 enrolled
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
Phase 2 Completed
25 enrolled 5 charts
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
130 enrolled
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2 Completed
31 enrolled
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase 2 Completed
44 enrolled
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Phase 2 Completed
35 enrolled